Lung Cancer

A substantial—and potentially growing—proportion of patients with non–small cell lung cancer are people who never, or only rarely, smoked.

Silvia Formenti, MD, chair of Radiation Oncology at Weill Cornell Medical College and radiation oncologist-in-chief at Weill Cornell Medicine and NewYorkPresbyterian Hospital, discusses combining radiotherapy with immunotherapy in non-small cell lung cancer (NSCLC).

The FDA has approved a non-alcohol formulation of docetaxel as a treatment for patients with breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer.

The FDA has granted a breakthrough therapy designation to the third-generation EGFR TKI BI-1482694 as a potential treatment for patients with EGFR T790M-positive non–small cell lung cancer.

Frontline treatment with afatinib reduced the risk of progression or death by 27% compared with gefitinib for patients with EGFR-mutant non–small cell lung cancer.

Treatment with pembrolizumab reduced the risk of death by 29% compared with docetaxel for patients with PD-L1-positive non–small cell lung cancer.

The FDA has extended the review period for rociletinib in patients with EGFR T790M-positive non–small cell lung cancer by 3 months, to allow ample time to review additional data.

The FDA has granted an accelerated approval to alectinib as a treatment for patients with metastatic ALK-positive non–small cell lung cancer following progression on crizotinib.

The FDA has granted a priority review to crizotinib as a treatment for patients with ROS1-positive metastatic non–small cell lung cancer.

Gregory Riely, MD Medical Oncologist, Vice Chair, Clinical Trials Office, Department of Medicine, Memorial Sloan Kettering, discusses the benefits and challenges of using next-generation sequencing to identify mutations in lung cancer.

As the class of agents targeting the PD-1/PD-L1 pathway expands in non–small cell lung cancer, so does the potential population of patients who would be candidates for the groundbreaking immunotherapy.

Suresh Ramalingam, MD, discusses the evolving role of checkpoint inhibitors in lung cancer and what challenges still remain.

Naiyer A. Rizvi, MD, discusses results of a study looking at the combination of the anti-PD-L1 immune checkpoint inhibitor durvalumab (MEDI4736) with the anti–CTLA-4 monoclonal antibody tremelimumab in patients with advanced non–small cell lung cancer.